聚焦AI+药物研发,阿斯利康“重仓”中国

Ofweek维科网
19 Jun

中国分子又出海了。6月13日,阿斯利康宣布,与石药集团达成合作。双方将利用石药集团的AI引擎双轮驱动的高效药物发现平台,开发新型口服小分子候选药物,首付款1.1亿美元,合作总额最高达53.3亿美元。BD对于当下的中国医药产业已经不是新鲜事,但这笔交易仍有足够的话题度。这是跨国大药企阿斯利康,今年在国内的又一次“出手”。在2月份,阿斯利康成交2025年第一单,宣布收购珐博进中国;到了3月份,阿斯利康...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10